Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

  title={Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.},
  author={Joseph P. McEvoy and Jeffrey A. Lieberman and T. Scott Stroup and Sonia M. Davis and Herbert Y. Meltzer and Robert A. Rosenheck and Marvin S. Swartz and Diana O. Perkins and Richard S. E. Keefe and Clarence E. Davis and Joanne B. Severe and John K. Hsiao},
  journal={The American journal of psychiatry},
  volume={163 4},
OBJECTIVE When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation. METHOD Ninety… 

Figures and Tables from this paper

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Among this group of patients with chronic schizophrenia who had just discontinued the older antipsychotic perphenazine, quetiapine and olanzapine were more effective than risperidone, as reflected by longer time to discontinuation for any reason.

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.

Olanzapine, quetiapines, and risperidone demonstrated comparable effectiveness in early-psychosis patients, as indicated by similar rates of all-cause treatment discontinuation.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?—A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting

When the first atypical antipsychotic is inadequate, switching to the second is worth trying, although some remain treatment-refractory, as in this open-label study of patients with schizophrenia.

Current status of clozapine in the United States

Based on clinical trials, meta-analyses, and large naturalistic studies clozapine is recommended as the most effective agent in schizophrenia, but the recommendations indicate that it should only be used when other agents fail.

Clozapine versus other atypical antipsychotics for schizophrenia.

Comparing the clinical effects of clozapine with other atypical antipsychotics, any dose and oral formulations, for people with schizophrenia or related disorders and finding a certain higher efficacy is suggested.

Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study

The efficacy of seven antipsychotic medications for the maintenance treatment appeared similar in early-stage schizophrenia, and special programs are needed to keep efficacy and safety of antipsychotics maintenance treatment for schizophrenia with early stage schizophrenia.

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

It is suggested that olanzapine is an effective treatment option for schizophrenia patients requiring a switch from risperidone, with similar proportions of patients achieving remission status at endpoint compared with ris peridone patients not requiring medication switch.



The Risks and Benefits of Clozapine versus Chlorpromazine

It is suggested that clozapine is well tolerated and may be therapeutically superior to chlorpromazine in treating psychotic behavior and agranulocytosis potential can be minimized by frequent white blood cell counts and removing nonresponding patients from treatment prior to the peak risk period.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.

Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review.

Clozapine treatment was quite likely delayed for longer than is clinically desirable and this delay may have important effects on quality of life, clinical outcome, and health resource utilization.

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.

Twenty-one patients with schizophrenia who met criteria for neuroleptic treatment resistance or intolerance participated in a crossover, placebo-controlled, double-blind comparison of long-term

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.

It is confirmed that treatment-resistant schizophrenic patients have more favorable outcomes when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric Rating Scale total score, categorical response rate, Scale for the Assessment of Negative Symptoms score, Simpson-Angus Rating Scale score, and compliance rate.

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

Clozapine has superior efficacy for treating positive symptoms in partially responsive outpatients with chronic schizophrenia, suggesting that it has utility for a broad spectrum of patients with schizophrenia beyond the most severely ill.

Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.

Compared with usual care, clozapine was associated with significantly greater reductions in side effects, disruptiveness, and hospitalization, but was not more effective in reducing symptoms or improving quality of life.

Patient response and resource management: another view of clozapine treatment of schizophrenia.

The cumulative benefit over several months of treatment and the broad range of symptoms involved in response are similar to those for typical neuroleptic drugs, suggesting that clozapine's superiority is based on greater effectiveness rather than a unique profile of treatment effects.

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

The CATIE schizophrenia trial blends features of efficacy studies and large, simple trials to create a pragmatic trial that will provide extensive information about antipsychotic drug effectiveness over at least 18 months.